Current Opinion in Hematology was launched in 1994. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of hematology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
Hal E. Broxmeyer
Dr Hal E. Broxmeyer is Distinguished Professor, Professor of Microbiology and Immunology, Mary Margaret Walther Professor Emeritus, and Co-Leader Program on Hematopoiesis, Malignant Hematology, and Immunology, Indiana University Simon Cancer Center, and former Chairman of Microbiology and Immunology and Scientific Director, Walther Oncology Center, at the Indiana University School of Medicine, Indianapolis, IN. He received a BS degree, Brooklyn College, City University of New York in 1966, an MS degree from Long Island University, Brooklyn Center in 1969 and a PhD from New York University in 1973. He did post-doctoral training in 1973–1975 at Kingston General Hospital, Queens University Kingston, Ontario, Canada. From 1975–1983 he worked at the Memorial Sloan Kettering Cancer Center (MSKCC) in NewYork City rising from the rank of Associate Researcher to that of Associate Member. He was also Assistant Professor of Biology, Sloan Kettering Division of Cornell University Graduate School of Medical Sciences, New York, before being recruited to the Indiana University School of Medicine in 1983 as an Associate Professor of Medicine. To date, he has published 781 scientific papers (539 refereed papers and 242 Reviews/Book Chapters). Broxmeyer's laboratory studies mechanisms regulating hematopoietic stem and progenitor cell, embryonic stem cell and induced pluripotent stem cell: proliferation, self-renewal, survival, differentiation and migration (homing/mobilization). He was involved in establishing the field of cord blood transplantation. His publications have been cited 42,697 times (Web of Science; WOS)/61,149 times (Google Scholar; GS) and the H-Factor for publications is 103 (WOS)/ 117 (GS) with i10 index = 554 (GS).
Dr Broxmeyer's Awards include: New York University Founders Day Award (1973); Mellor Award (2nd prize 1976; 1st prize 1977) and Boyer Award (1983) from MSKCC; Special Fellow (1976–1978) and Scholar Award (1978–1983) from the Leukemia Lymphoma Society; Merit Award, National Cancer Institute (1987–1995); Variety Club Award (1992 and 1993), Indiana; Gold Medal of City of Paris (1993); World of Difference Award, Indiana Health Industry Forum (1997); Who's Who in Health Care, Indianapolis Business Journal (IBJ) (2002); Health Care Heroes Award, IBJ (2002); Karl Landsteiner Award, American Association of Blood Banks (2002); Prestigious External Award Recognition, IUPUI (2003); Distinguished Alumni Award, Long Island University (2005); Joseph T. Taylor Excellence in Diversity Award, Indiana University (2006); Dirk van Bekkum Award, Autologous Blood and Bone Marrow Society (2006); E. Donnall Thomas Prize and Lecture, American Society of Hematology (2007); Glenn W. Irwin Jr. M.D., Distinguished Faculty Award, Indiana University School of Medicine Alumni Association (2008); State of Indiana General Assembly House Resolution No. 46 (2008); Mission Advancement Award, Leukemia Lymphoma Society (2008); Cord Blood Pioneering Award, Int. Cord Blood Symposium (2008); Till and McCullough Award, Canadian Bone Marrow Transplant Group (2010); Donald Metcalf Award, Int. Soc. Expt. Hematol. (2011); Elected Fellow of the American Association for the Advancement of Science (AAAS) (2013); Honorary Professorship, Peking Union Medical College, Beijing, China (2014); Thought Leader Award, 15th Annual Cord Blood Symposium (2017); and NHLBI Outstanding Investigator Award (R35) (2018).
Dr Broxmeyer is a former President of the American Society of Hematology (ASH; 2010), former President of the International Society for Experimental Hematology (ISEH, 1990, 1991), former Chairman, and member, Board of Scientific Councilors, National Space Biomedical Research Institute (NSBRI/NASA, 1998–2006), and Chairman Emeritus, Board of Directors, National Disease Research Interchange, Philadelphia, PA.
Ari Melnick, MD, is the Gebroe Family Professor of Hematology/Oncology and a Professor of Medicine and Pharmacology at Weill Cornell Medical College (WCMC) in New York City, USA. He is Chair of the Hematologic Malignancies Program of the Weill Cornell Cancer Center and is also Director of the Raymond and Beverly Sackler Center for Biomedical and Physical Sciences and Director of the Epigenomics Core Facility, both of which are at WCMC. Dr Melnick was raised in Argentina and received his medical degree from the University of Buenos Aires, Argentina.
He completed a residency in internal medicine and a fellowship in hematology/oncology, as well as a postdoctoral fellowship at the Mount Sinai School of Medicine in New York City, USA.
Dr Melnick's research interests include the biology and molecular targeting of B-cell lymphomas, targeting transcriptional and epigenetic repressors for cancer therapy, and identifying the epigenetic basis of hematologic malignancies. He and his research associates have also developed novel therapies to correct aberrant transcriptional regulation and signaling in these tumors. Dr Melnick has been Scientific Chair of the American Society of Hematology (ASH) annual meeting and has organized several meetings in the areas of epigenetics and hematologic malignancies.
Dr Melnick is a past ASH Faculty Scholar and Kimmel Foundation Scholar, and he has been recognized for this work by the Leukemia & Lymphoma Society. He is also co-leader of the New York Leukemia Working Group.
Dr Melnick has authored or coauthored more than 150 published manuscripts in journals such as Nature, Science, Cell, Cancer Cell, Nature Medicine, Nature Immunology, and the New England Journal of Medicine.